Overview

• Edgewell Q4 net sales rose 3.8%, slightly beating analyst expectations

• Adjusted EPS for Q4 missed analyst expectations

• On Nov 13, company announced $100 mln share repurchase authorization

• Edgewell to sell Feminine Care business to Essity for $340 mln

Outlook

• Edgewell expects 2026 reported net sales to increase 0.5% to 3.5%

• Company projects 2026 GAAP EPS between $1.10 and $1.50

• Adjusted EPS for 2026 expected to be $2.15 to $2.55

Result Drivers

• INTERNATIONAL GROWTH - Co reports 6.9% organic sales growth in international markets, driven by volume and price gains

• PROMOTIONAL IMPACT - Increased promotional levels in North America offset volume gains, leading to a 0.6% organic sales decline

• DIVESTITURE STRATEGY - Sale of Feminine Care business to Essity for $340 mln marks strategic shift to focus on core personal care segments

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the personal products peer group is "hold."

• Wall Street's median 12-month price target for Edgewell Personal Care Co is $25.50, about 25.8% above its November 12 closing price of $18.91

• The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nPn7HHbzka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)